MODERNA, INC. 
These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax®), Moderna’s licensed vaccine for the condition.
“We are excited to announce our fourth infectious disease vaccine programme with positive Phase III data,” stated
Moderna reveals optimistic data for influenza-COVID-19 vaccine
A promising mRNA vaccine
What the clinical data showed
Findings from the NextCOVE Phase III pivotal trial showed that mRNA-1283 facilitated a higher immune response in patients against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to
Importantly, this benefit was mostly observed in individuals who were aged over 65 years old.
Additionally, mRNA-1283 was found to have a similar safety profile to Moderna’s approved vaccines for COVID-19. In the Phase III clinical trial, the most common solicited adverse events included injection site pain (local) and headache, fatigue, myalgia and chills (systematic),
Based on the storage, shelf life and pre-filled syringe presentation of the mRNA-1283, the COVID-19 vaccine could support increased access of the treatment into new settings, according to
Further details
In
The post Next-gen Moderna COVID-19 vaccine shows promise appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source
